Tianjin Biopharmaceutical Innovation Park To Start Operation In April
This article was originally published in PharmAsia News
Executive SummaryChina's biopharmaceutical international innovation park, sited in Tianjin Economic-Technological Development Area, has completed its phase one construction and will go into operation in April. To date, the park has received more than 170 domestic and overseas applications of R&D projects; it has already confirmed the location of four industrial companies with investment of over RMB100 million ($14.61 million) each. Tianjin International Biomedical Research Institute, the park's core component, will by year end establish a series of technical platforms including its clinical trial center, drug analysis and testing center, and information center. By the end of 2010, the park will be a world-class biopharmaceutical R&D base with more than 100 R&D teams and 1,000 people. (Click here for more - Chinese Language)
You may also be interested in...
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.